<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686501</url>
  </required_header>
  <id_info>
    <org_study_id>[18F] MNI-968</org_study_id>
    <nct_id>NCT03686501</nct_id>
  </id_info>
  <brief_title>D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562</brief_title>
  <official_title>An Open-Label Study To Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [18F]MNI-968 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invicro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invicro</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of&#xD;
      PF-06412562.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral&#xD;
           administration of PF-06412562&#xD;
&#xD;
        -  To assess the relationship of D1 RO in the striatum versus plasma exposure of&#xD;
           PF-06412562 after a single oral administration.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      • To evaluate the plasma exposure of PF-06412562for the duration of PET scan following a&#xD;
      single oral administration of PF-06412562.&#xD;
&#xD;
      Safety Objectives:&#xD;
&#xD;
      • To evaluate the safety and tolerability of PF-06412562 of single oral doses of PF-06412562.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">March 28, 2019</completion_date>
  <primary_completion_date type="Actual">March 28, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) with Ligand [18F]MNI-968</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>PF-06412562</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562</intervention_name>
    <description>Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two [18F]MNI-968 injections</description>
    <arm_group_label>PF-06412562</arm_group_label>
    <other_name>[18F]MNI-968 (PF-06730110)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject eligibility should be reviewed and documented by an appropriately qualified member&#xD;
        of the investigator's study team before subjects are included in the study.&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          1. Signed and dated informed consent document indicating that the subject has been&#xD;
             informed of all pertinent aspects of the study prior to the initiation of any study&#xD;
             assessments.&#xD;
&#xD;
             Healthy male subjects between the ages of 20 and 55 years, inclusive. (Healthy is&#xD;
             defined as no clinically relevant abnormalities identified by a detailed medical&#xD;
             history, full physical examination, including blood pressure and pulse rate&#xD;
             measurement, 12-lead ECG and clinical laboratory tests, in the opinion of the&#xD;
             investigator).&#xD;
&#xD;
          2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).&#xD;
&#xD;
          3. Male subjects must not donate sperm for the study duration.&#xD;
&#xD;
          4. Subjects must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory test and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
          1. Evidence or history of clinically significant hepatic, renal, cardiovascular,&#xD;
             endocrine, hematologic, gastrointestinal, pulmonary, neurologic, oncologic,&#xD;
             psychiatric, or allergic disease (including drug allergies, but excluding untreated,&#xD;
             asymptomatic, seasonal allergies at time of dosing). This also includes subjects with&#xD;
             previous history of epilepsy or seizures, clinically significant abnormal&#xD;
             electroencephalogram (EEG), febrile convulsion, head injury with significant sequelae,&#xD;
             psychiatric illness, attempted suicide or suicidal ideation.&#xD;
&#xD;
          2. Any condition possibly affecting drug absorption (eg, gastrectomy)&#xD;
&#xD;
          3. A positive urine drug screen (confirmed by repeat) Protocol 4006 Version 1.0; 20 April&#xD;
             2018 Confidential and Proprietary&#xD;
&#xD;
          4. History of regular alcohol consumption exceeding 14 drinks/week for males (1 drink = 5&#xD;
             ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard&#xD;
             liquor) within 6 months of screening.&#xD;
&#xD;
          5. Treatment with an investigational drug within 30 days (or as determined by the local&#xD;
             requirement, whichever is longer) or 5 half-lives preceding the dose of study&#xD;
             medication.&#xD;
&#xD;
          6. Screening supine blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic),&#xD;
             following at least 5 minutes of rest. If blood pressure (BP) is ≥140 mm Hg (systolic)&#xD;
             or ≥90 mm Hg (diastolic), the BP should be repeated two more times and the average of&#xD;
             the three BP values should be used to determine the subject's eligibility.&#xD;
&#xD;
          7. 12-lead ECG demonstrating QTc &gt;450 msec or a QRS interval &gt;120 msec at screening. If&#xD;
             QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more&#xD;
             times and the average of the three QTc or QRS values should be used to determine the&#xD;
             subject's eligibility.&#xD;
&#xD;
          8. Males of childbearing potential who are unwilling or unable to use a highly effective&#xD;
             method of contraception as outlined in this protocol for the duration of the study and&#xD;
             for at least 28 days after the last dose of investigational product.&#xD;
&#xD;
          9. Use of prescription drugs within 7 days or 5 half-lives (whichever is longer) prior to&#xD;
             the dose of study medication. As an exception, acetaminophen/paracetamol may be used&#xD;
             &quot;as needed&quot; (prn) and only at doses of ≤1 g/day.&#xD;
&#xD;
         10. Blood donation or loss (excluding plasma donations) of approximately 1 pint (500 mL)&#xD;
             or more within 56 days prior to dosing.&#xD;
&#xD;
         11. History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
         12. Unwilling or unable to comply with the Life Style Guidelines described in this&#xD;
             protocol.&#xD;
&#xD;
         13. Any severe acute or chronic medical or psychiatric condition or laboratory abnormality&#xD;
             that may increase the risk associated with study participation or investigational&#xD;
             product administration or may interfere with the interpretation of study results and,&#xD;
             in the judgment of the investigator, would make the subject inappropriate for entry&#xD;
             into this study.&#xD;
&#xD;
         14. A lifetime history of seizure disorder of any etiology, inclusive of childhood&#xD;
             seizures.&#xD;
&#xD;
         15. Subjects who are investigational site staff members directly involved in the conduct&#xD;
             of the study and their family members, site staff members otherwise supervised by the&#xD;
             Investigator, or subjects who are Pfizer or Invicro employees directly involved in the&#xD;
             conduct of the study.&#xD;
&#xD;
         16. Use of drugs or consumption of foods/food products which inhibit CYP3A4 (including,&#xD;
             but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,&#xD;
             nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, amprenavir, aprepitant,&#xD;
             diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, cimetidine,&#xD;
             grapefruit, grapefruit juice) within 7 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
             Protocol 4006 Version 1.0; 20 April 2018 Confidential and Proprietary&#xD;
&#xD;
         17. Evidence of orthostatic symptoms (eg, dizziness upon standing) or systolic blood&#xD;
             pressure (BP) drop ≥20 mm Hg or diastolic BP drop ≥10 mm Hg from supine to standing&#xD;
             assessment at screening. Abnormal values on Day 2 are left to the judgment of the&#xD;
             investigator. Resting pulse rate &lt; 45 or &gt;100 bpm.&#xD;
&#xD;
         18. Any subject who is likely to be hospitalized (for any reason) during the study.&#xD;
&#xD;
         19. Subjects with pacemakers, aneurysm clips, artificial heart valves, ear implants,&#xD;
             cerebrospinal fluid (CSF) shunts, metal fragments or foreign objects in the eyes,&#xD;
             skin, or body, claustrophobia or any other condition that would contraindicate a brain&#xD;
             MRI scan.&#xD;
&#xD;
         20. Inability to lie still within the environment of the MRI and PET scanners for the&#xD;
             required period to acquire images.&#xD;
&#xD;
         21. Subjects with any anatomical abnormality in the head that would either preclude or&#xD;
             tend to confound the analysis of study data, including any clinically significant&#xD;
             abnormal findings from MRI of the head at screening.&#xD;
&#xD;
         22. Prior participation in other research protocols or clinical care within the past year&#xD;
             in addition to the radiation exposure expected in this clinical study, such that&#xD;
             radiation exposure exceeds the effective dose of 50 mSv, equivalent with the&#xD;
             acceptable annual limits established by the US Federal Guidelines.&#xD;
&#xD;
         23. Current, past or anticipated exposure to radiation for the past 5 years (for&#xD;
             oncology-related radiation, refer to exclusion criteria #. This includes radiation&#xD;
             therapy).&#xD;
&#xD;
         24. Subjects with a history of poor compliance history of refusing to comply with&#xD;
             administered medications or inpatient/ research unit rules, or a history of demanding&#xD;
             discharge from inpatient treatment against medical advice.&#xD;
&#xD;
         25. Subjects with screening laboratory test results that deviate from the upper or lower&#xD;
             limits of the reference range, except for not clinically significant values, as&#xD;
             determined by the investigator. Aspartate aminotransferase (AST) or Alanine&#xD;
             transaminase (ALT) must be ≤2 X the upper limit of reference range, and total&#xD;
             bilirubin must be within 1.5 X the upper limit of reference range at screening.&#xD;
&#xD;
         26. Subjects with a positive test for hepatitis B (HBsAg), hepatitis C antibody (HCV),&#xD;
             Human Immunodeficiency Virus (HIV)1/HIV2 antibody/antigen.&#xD;
&#xD;
         27. Subjects who have answered &quot;yes&quot; to &quot;Suicidal Ideation&quot; Item 4 or Item 5 on the&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS) at screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Invicro</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.invicro.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HV</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

